PL2467489T3 - Wytwarzanie opartych na bakulowirusie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych - Google Patents

Wytwarzanie opartych na bakulowirusie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych

Info

Publication number
PL2467489T3
PL2467489T3 PL10743083T PL10743083T PL2467489T3 PL 2467489 T3 PL2467489 T3 PL 2467489T3 PL 10743083 T PL10743083 T PL 10743083T PL 10743083 T PL10743083 T PL 10743083T PL 2467489 T3 PL2467489 T3 PL 2467489T3
Authority
PL
Poland
Prior art keywords
baculovirus
based production
biopharmaceuticals
free
baculoviral virions
Prior art date
Application number
PL10743083T
Other languages
English (en)
Inventor
Otto-Wilhelm Merten
Martin Marek
Oers Monique Van
Original Assignee
Genethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon filed Critical Genethon
Publication of PL2467489T3 publication Critical patent/PL2467489T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14151—Methods of production or purification of viral material
    • C12N2710/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL10743083T 2009-08-17 2010-08-05 Wytwarzanie opartych na bakulowirusie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych PL2467489T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305761A EP2292781A1 (en) 2009-08-17 2009-08-17 Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
EP10743083.7A EP2467489B1 (en) 2009-08-17 2010-08-05 Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
PCT/EP2010/061456 WO2011020710A2 (en) 2009-08-17 2010-08-05 Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions

Publications (1)

Publication Number Publication Date
PL2467489T3 true PL2467489T3 (pl) 2015-10-30

Family

ID=41203903

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10743083T PL2467489T3 (pl) 2009-08-17 2010-08-05 Wytwarzanie opartych na bakulowirusie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych
PL16205440T PL3187589T3 (pl) 2009-08-17 2010-08-05 Oparte na bakulowirusie wytwarzanie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16205440T PL3187589T3 (pl) 2009-08-17 2010-08-05 Oparte na bakulowirusie wytwarzanie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych

Country Status (10)

Country Link
US (4) US8993317B2 (pl)
EP (4) EP2292781A1 (pl)
CN (1) CN102686732A (pl)
CA (2) CA3050271A1 (pl)
DK (3) DK2933336T3 (pl)
ES (3) ES2787706T3 (pl)
HU (1) HUE025056T2 (pl)
PL (2) PL2467489T3 (pl)
PT (3) PT2467489E (pl)
WO (1) WO2011020710A2 (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292781A1 (en) * 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
US20140287460A1 (en) * 2011-07-27 2014-09-25 Gbiotech Sarl Production of recombinant protein in insect cells using a baculovirus expression system
FR2978456B1 (fr) * 2011-07-27 2015-02-20 Genethon Systeme baculoviral pour l'expression d'un vecteur de therapie genique
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US9982239B2 (en) 2012-06-12 2018-05-29 Alternative Gene Expression S.L. Baculoviral DNA elements for the expression of recombinant proteins in a host cell
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
ES2865487T3 (es) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Métodos y composiciones para vectores virales que evaden los anticuerpos
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR102427379B1 (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
JP7106461B2 (ja) * 2016-06-07 2022-07-26 セファイド 熱安定性ポリメラーゼ阻害剤組成物及び方法
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
EP3774852A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Antibody-evading virus vectors
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
KR20210019996A (ko) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 조성물 및 방법
WO2019237376A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 TXGP1基因定点整合至Raji细胞的方法及其应用
WO2019237377A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 一种将SLEB2基因定点整合至Jurkat细胞的方法及其应用
WO2019237374A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 Mtabc3基因定点整合至a375细胞的方法及其应用
CN108823176B (zh) * 2018-07-20 2021-09-28 山西大学 一种重组杆状病毒及其构建方法和应用
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
CN108998455B (zh) * 2018-08-13 2021-03-16 西南大学 家蚕核型多角体病毒诱导型39k启动子及其重组载体和应用
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN111434774B (zh) * 2019-01-11 2023-06-23 陕西杆粒生物科技有限公司 一种解除高滴度抑制的杆状病毒表达载体
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
EP3947700A4 (en) 2019-04-01 2023-01-04 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
JP7805169B2 (ja) * 2019-06-26 2026-01-23 ビロベク，インコーポレイテッド バキュロウイルス発現系
JP2022551739A (ja) 2019-10-17 2022-12-13 ストライドバイオ，インコーポレイテッド ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
US12611436B2 (en) 2019-10-17 2026-04-28 Sarepta Therapeutics, Inc. AAV transfer cassette
CN110940807A (zh) * 2019-11-08 2020-03-31 江苏科技大学 研究家蚕基因抑制BmNPV DNA复制相关基因的表达的方法
AU2021328475A1 (en) 2020-08-19 2023-03-16 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
WO2022046665A1 (en) * 2020-08-23 2022-03-03 Bioverativ Therapeutics Inc. MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA)
BR112023006305A2 (pt) 2020-10-09 2023-05-09 Tenaya Therapeutics Inc Métodos e composições de terapia gênica com placofilina-2
CN115491377B (zh) * 2021-06-18 2025-09-16 北京三诺佳邑生物技术有限责任公司 一种诱导rna干扰和降低并清除细胞中病毒污染的核苷酸序列及应用
CN115491436A (zh) * 2021-06-18 2022-12-20 舒泰神（北京）生物制药股份有限公司 一种用于检测杆状病毒残留dna的引物、探针及方法
MX2024002333A (es) * 2021-08-23 2024-03-07 Bioverativ Therapeutics Inc Sistema de expresion de baculovirus.
CN114058598B (zh) * 2021-11-04 2023-04-28 中国科学院精密测量科学与技术创新研究院 新的重组杆状病毒基因组插入位点及其应用
WO2023201207A1 (en) 2022-04-11 2023-10-19 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
CN118956967A (zh) * 2024-04-17 2024-11-15 和元生物技术（上海）股份有限公司 核酸分子、包含其的重组杆状病毒及其应用
CN120137918B (zh) * 2025-05-12 2025-09-02 中国林业科学研究院高原林业研究所 重组dsRNA-杆状病毒及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
CN1062601C (zh) * 1992-03-24 2001-02-28 剑桥药物研究有限公司 病毒疫苗
FR2756297B1 (fr) * 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
GB9919409D0 (en) * 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
JP2005532829A (ja) * 2002-07-18 2005-11-04 インヴィトロジェン コーポレーション 組換え部位を含むウイルスベクター
US20060166363A1 (en) * 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
EP2292781A1 (en) * 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions

Also Published As

Publication number Publication date
ES2542740T3 (es) 2015-08-11
US11236307B2 (en) 2022-02-01
EP3187589A3 (en) 2017-09-20
CA3050271A1 (en) 2011-02-24
ES2627744T3 (es) 2017-07-31
EP2467489A2 (en) 2012-06-27
PT2467489E (pt) 2015-09-04
EP2933336A2 (en) 2015-10-21
US20150252335A1 (en) 2015-09-10
PL3187589T3 (pl) 2020-06-29
CA2771250C (en) 2019-09-17
US8993317B2 (en) 2015-03-31
CA2771250A1 (en) 2011-02-24
EP2467489B1 (en) 2015-05-27
US20120149010A1 (en) 2012-06-14
EP2933336A3 (en) 2015-12-02
PT2933336T (pt) 2017-06-12
DK2933336T3 (en) 2017-06-12
EP3187589A2 (en) 2017-07-05
US20200002683A1 (en) 2020-01-02
DK2467489T3 (en) 2015-07-20
US9862934B2 (en) 2018-01-09
WO2011020710A3 (en) 2011-05-05
WO2011020710A2 (en) 2011-02-24
EP2292781A1 (en) 2011-03-09
DK3187589T3 (da) 2020-04-14
ES2787706T3 (es) 2020-10-16
CN102686732A (zh) 2012-09-19
HUE025056T2 (en) 2016-01-28
EP3187589B1 (en) 2020-02-12
PT3187589T (pt) 2020-05-07
US20180127728A1 (en) 2018-05-10
US10428315B2 (en) 2019-10-01
EP2933336B1 (en) 2017-03-29

Similar Documents

Publication Publication Date Title
PL2467489T3 (pl) Wytwarzanie opartych na bakulowirusie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych
PL2289864T3 (pl) Proces otrzymywania związków fluorowych
SI2496562T1 (sl) Postopek priprave kalkobutrola
PL2604268T3 (pl) Sposób wytwarzania pochodnych tiazolu
PT2913337T (pt) Processo para a produção de sofosbuvir
IL220170A0 (en) New process for the preparation of dronedarone
IL216322A0 (en) Process for the production of dronedarone intermediates
IL216942A0 (en) Process for the manufacture of alkenones
IL214906A (en) A process for making Iwan
ZA201105709B (en) Process for the synthesis of cleistanthin
EP2397438A4 (en) METHOD FOR PRODUCING A FLUOR COMPOUND
EP2464584A4 (en) SHIPPING OF LIQUIDS
IL217139A0 (en) Process for the preparation of arylpyridinyl compounds
IL219111A0 (en) Process for the manufacture of organic compounds
ZA201107259B (en) Process for the synthesis of a propargylic alcohol
ZA201106175B (en) Chemical process for the production of haloalkenone ethers
EP2423212A4 (en) PROCESS FOR PREPARING A 2-AZAADAMANTAN COMPOUND FROM A BICYCLOCARBAMATE COMPOUND
EP2393786A4 (en) NEW POLYMORPHIC FROM LOPINAVIR
IL215022A0 (en) Novel process for the preparation of enaminocarbonyl compounds
FI20095142L (fi) Laitteisto lasimateriaalin valmistamiseksi
IL217460A0 (en) Novel process for the preparation of 4-aminobut-2-enolides
IL217402A0 (en) Continuous flow process for the preparation of sulphoxide compounds
GB0905895D0 (en) Process for the preparation of chalcogenone compounds
SI2387557T1 (sl) Postopek za pripravo N-(5-(3-dimetilamino-akriloil)-2-fluorofenil)-N-metil-acetamida
GB0915850D0 (en) Inspection of glazing components